Solanezumab

DRUG9 trials

Conditions

Alzheimer's DiseaseAlzheimers DiseaseAlzheimers Disease, FamilialCognition DisordersDementiaHealthyMild Cognitive Impairment

Phase 1

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

TerminatedNCT02614131

Eli Lilly and CompanyAlzheimer's Disease, Healthy, Mild Cognitive Impairment

Start: 2015-12-31End: 2016-12-31Updated: 2020-06-17

Phase 2

Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

CompletedNCT00749216

Eli Lilly and CompanyAlzheimer's Disease

Start: 2008-09-30End: 2009-07-31Updated: 2010-06-02

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

CompletedNCT01148498

Eli Lilly and CompanyAlzheimer's Disease

Start: 2010-08-31End: 2012-08-31Target: 55Updated: 2012-09-25

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Active, not recruitingNCT01760005

Washington University School of MedicineAlzheimers Disease, Alzheimers Disease, Familial, Dementia

Start: 2012-12-01End: 2028-07-01Target: 490Updated: 2026-02-13

CompletedNCT04623242

Washington University School of MedicineAlzheimers Disease, Alzheimers Disease, Familial, Dementia

Start: 2012-12-31End: 2020-03-06Updated: 2022-09-22

Phase 3

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

TerminatedNCT01127633

Eli Lilly and CompanyAlzheimer's Disease

Start: 2010-12-31End: 2017-02-28Updated: 2019-10-08

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

TerminatedNCT01900665

Eli Lilly and CompanyAlzheimer's Disease

Start: 2013-07-31End: 2017-02-28Updated: 2019-10-09

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

CompletedNCT02008357

Eli Lilly and CompanyCognition Disorders

Start: 2014-02-28End: 2023-06-08Updated: 2023-12-28

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

TerminatedNCT02760602

Eli Lilly and CompanyAlzheimer's Disease

Start: 2016-06-30End: 2017-05-31Updated: 2019-10-10

2026-01-011 citations

Independent effects of white matter lesion volume and APOE ɛ4 on ARIA-H in A4 Study.

2025-10-01

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

Alzheimer s & Dementia2025-09-013 citations

The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

Alzheimer s & Dementia2025-09-011 citations

The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.

2025-07-01

Association of Alzheimer's disease concerns with amyloid burden and lifestyle behaviors in cognitively unimpaired older adults

Alzheimer s & Dementia2025-06-01

Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid

Neurology2025-05-292 citations

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

2025-04-0117 citations

MRI and PET findings with long‐term gantenerumab treatment: results from the DIAN‐TU trial